“Congress’ ability to curb the explosive rise in drug costs is a bellwether of the political prospects for health care reform,” writes Merrill Goozner. “Along with eliminating unnecessary payments to insurance firms (like the 12 percent bump they get for selling Medicare Advantage plans), curbing Big Pharma’s voracious appetite for selling overpriced and often unnecessary drugs is the low-hanging fruit of cost control.” In order to prevent this from happening, therefore, drug companies are wooing Democrats, ramping up campaign contributions … Continue reading →